Primary varicose veins: Altered transcription of VEGF and its receptors (KDR, flt-1, soluble flt-1) with sapheno-femoral junction incompetence

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 3, 2004, Pages 259-268

  Hollingsworth, Simon J ^a   Powell, G L ^a   Barker, S G E ^a   Cooper, D G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

flt 1; KDR; s.flt 1; Sapheno femoral junction; Varicose veins; Vascular endothelial growth factor; Venous incompetence

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; ECHOGRAPHY; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE; SAPHENOUS VEIN; STATISTICAL ANALYSIS; VARICOSIS; VEIN INSUFFICIENCY;

EID: 1442280821     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2003.12.015     Document Type: Article

References (62)

1. Coleridge Smith PD. The management of chronic venous disorders of the leg: an evidence based report of an International Task Force. Phlebology 1999;14(Suppl. 1):23-35.
2. Browse NL, Burnand KG, Irvine AT, Wilson NM. Diseases of the veins, 2nd ed. London: Edward Arnold, 1999: 145-162.
3. Cornu-Thenard A, Bolvin P, Baud JM, Vincenzi I, Carpenter PH. Importance of the familial factor in varicose disease. Clinical study of 134 families. J Dermatol Surg 1994;20:316-318.
4. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Commun Health 1999;53:149-153.
5. Sadick NS. Predisposing factors of varicose and telangectasic leg veins. J Dermatol Surg Oncol 1992;18:883-886.
6. Abramson JH, Hopp C, Epstein LM. The epidemiology of varicose veins. A survey in western Jerusalem. J Epidemiol Commun Health 1981;35:213-217.
7. Labropoulos N, Delis K, Nicolaides AN, Leon M, Ramaswami G, Volteas N. The role of the distribution and anatomic extent of reflux in the development of signs and symptoms in chronic venous insufficiency. J Vasc Surg 1996;23:504-510.
8. Sakurai T, Gupta PC, Matsushita M, Nikishimi N, Nimura Y. Correlation of the anatomical distribution of venous reflux with clinical symptoms and venous haemodynamics in primary varicose veins. Br J Surg 1998;85:213-216.
9. Allan PL, Bradbury AW, Evans CJ, Lee AJ, Vaughan Ruckley C, Fowkes FGR. Patterns of reflux and severity of varicose veins in the general population - Edinburgh Vein Study. Eur J Vasc Endovasc Surg 2000;20:470-477. doi:10.1053/ejvs.2000.1223.
10. Callam MJ. Epidemiology of varicose veins. Br J Surg 1994;81: 167-173.
11. Varicose vein: pathology. In: Browse NL, Burnand KG, Irvine AT, Wilson NM, eds. Diseases of the veins, 2nd ed. London: Edward Arnold, 1999: 145-158.
12. Farbiszewski R, Glowinski J, Makarewica-Plonska N, Chwiecko M, Ostapowicz R, Glowinski S. Oxygen-derived free radicals as mediators of varicose vein wall damage. Vasc Surg 1996;30:47-52.
13. Yamada T, Tomita S, Mori M, Sasatomi E, Suenaga E, Itoh T. Increased mast cell infiltration in varicose veins of the lower limbs: a possible role in the development of varices. Surgery 1996; 119:494-497.
14. Deby C, Hariton C, Pincemail J, Coget J. Decreased tocopheral concentration of varicose veins is associated with a decrease in antilipoperoxidant activity without similar changes in plasma. Phlebology 1989;4:113-121.
15. Garcia-Rospide V, Penafiel-Marfil R, Moreno-Padilla F, Gonzalez-Rios J, Ramos Bruno JJ, Ros Die E. Enzymatic and isoenzymatic study of varicose veins. Phlebology 1991;6:187-198.
16. Crotty TP. Is circulating noradrenaline the cause of varicose veins? Med Hypotheses 1991;34:243-251.
17. Moller A, Henz BM, Grutzkau A, Lippert U, Aragane Y, Schwarz T, Kruger-Krasagakes S. Comparative cytokine gene expression: regulation and release by human mast cells. Immunology 1998;93:289-295.
18. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 2000;192:105-112.
19. Psaila JV, Melhuish J. Viscoelastic properties and collagen content of the great saphenous vein in normal and varicose veins. Br J Surg 1989;76:37-40.
20. Svejcar J, Prerovsky I, Linhart J, Kruml J. Content of collagen, elastin and hexosamine in primary varicose veins. Clin Sci 1963; 24:325-330.
21. Travers JP, Brookes CE, Evans J, Baker DM, Kent C, Makin GS, Mayhew TM. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996;11:230-237.
22. Porto LC, da-Silveira PR, de-Carvalho JJ, Panico MD. Connective tissue accumulation in the muscle layer in normal and varicose saphenous veins. Angiology 1995;46:243-249.
23. Hollingsworth SJ, Tang CB, Barker SGE. Primary varicose veins in the presence of an intact sapheno-femoral junction. Phlebology 2001;16:68-72.
24. Abu-Own A, Scurr JH, Coleridge-Smith PD. Saphenous vein reflux without incompetence at the saphenofemoral junction. Br J Surg 1994;81:1452-1454.
25. Rose SS, Ahmed A. Some thoughts on the aetiology of varicose veins. J Cardiovasc Surg Torino 1986;27:534-543.
26. Haimovici H. Role of precapillary arteriovenous shunting in the pathogenesis of varicose veins and its therapeutic implications. Surgery 1987;101:515-522.
27. Biagi G, Lapilli A, Zendron R, Piccinni L, Coccheri S. Prostanoid production in varicose veins: evidence for decreased prostacyclin with increased thromboxane A2 and prostaglandin E2 formation. Angiology 1988;39:1036-1042.
28. Blochl-Daum B, Schuller-Petrovic S, Wolzt M, Korn A, Bohler K, Eichler HG. Primary defect in alpha-adrenergic responsiveness in patients with varicose veins. Clin Pharmacol Ther 1991;49:49-52.
29. Thulesius O, Said S, Shuhaiber H, Neglen P, Gjores JE. Endothelial mediated enhancement of noradrenaline induced vasoconstriction in normal and varicose veins. Clin Physiol 1991; 11:153-159.
30. Lowell RC, Gloviczki P, Miller VM. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992;16:679-686.
31. Schuller-Petrovic S, Siedler S, Kern T, Meinhart J, Schmidt K, Brunner F. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol 1997;122:772-778.
32. Hollingsworth SJ, Tang CB, Barker SGE. The effects of heparin on cultured explants of varicose great saphenous vein. Phlebology 2001;16:60-67.
33. Cheatle TR, Scott HJ, Stibe EC. The effect of venous hypertension on the microcirculation. In: Coleridge Smith PD, ed. Microcirculation in Venous Disease, 2nd ed. Texas USA: Landes Bioscience, 1998: 63-81.
34. Michiels C, Arnould T, Thibaut Vercruyssen R, Bouaziz N, Janssens D, Remacle J. Perfused human saphenous veins for the study of the origin of varicose veins: role of the endothelium and of hypoxia. Int Angiol 1997;16:134-141.
35. Michiels C, Arnould T, Janssens D, Bajou K, Geron I, Remacle J. Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. Int Angiol 1996;15:124-130.
36. Ali MH, Schlidt SA, Chandel NS, Hynes KL, Schumacker PT, Gewertz BL. Endothelial permeability and IL-6 production during hypoxia: role of ROS in signal transduction. Am J Physiol 1999;277:L1057-L1065.
37. Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia promotes leukocyte-endothelial adherence via reactive oxidant generation. J Appl Physiol 1999;87:1734-1740.
38. Kalra VK, Shen Y, Sultana C, Rattan V. Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Am J Physiol 1996;271:H2025-H2034.
39. Lewis JS, Lee JA, Underwood JC, Harris AL, Lewis CE. Macrophages responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 1999;66:889-900.
40. Shields DA, Andaz AK, Sarin S, Scurr JH, Coleridge Smith PD. Neutrophil activation in experimental ambulatory venous hypertension. Phlebology 1994;9:119-124.
41. Servos S, Zachary I, Martin JF. VEGF modulates NO production: the basis of a cytoprotective effect? Cardiovasc Res 1999;41:509-510.
42. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603-606.
43. Tomasian D, Keaney Jr JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res 2000;47:426-435.
44. Hollingsworth SJ, Tang C-B, Dialynas M, Barker SG. Varicose veins: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide. Eur J Vasc Endovasc Surg 2001;22:551-556. doi:10.1053/ejvs.2001.1520.
45. Bradbury A, Evans C, Allan P, Lee A, Ruckley CV, Fowkes FG. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ 1999;318:353-356.
46. Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol 2001;30:846-852.
47. Franks PJ, Wright DD, Moffatt CJ, Stirling J, Fletcher AE, Bulpitt CJ, McCollum CN. Prevalence of venous disease: a community study in west London. Eur J Surg 1992;158:143-147.
48. Arnoldi CC. The aetiology of primary varicose veins. Dan Med Bull 1957;4:102-107.
49. Dodd H, Cockett FB. The pathology and surgery of the veins of the lower limb. Edinburgh: Livingstone, 1956. p. 3.
50. Trendelenburg F. Ueber die unterbindung der vena saphena magna bie unterschenkel varicen. Beitr Klin Chir 1890-1891;7: 195-210.
51. Shoab SS, Scurr JH, Coleridge Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg 1998;28:535-540.
52. Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 1997; 26:61-69.
53. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Benedetto FA. Plasma endothelin-1 release in normal and varicose saphenous veins. Angiology 1997;48:769-774.
54. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-328.
55. Blann AD, Belgore FM, McCollum CN, Silverman SL, Lip PL, Lip GYH. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002;102: 187-194.
56. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci (Lond) 2001;100:567-575.
57. Belgore FM, Blann AD, Li Saw Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001;87:805-807. see also A9.
58. Graubert MD, Ortega MA, Kessel B, Mortola JF, Irulela Arispe ML. Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFlt-1 Am J Pathol 2001;158:1399-1410.
59. Ahmed A, Dunk C, Ahmed S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta 2000; (Suppl. A):S16-S24.
60. Hollingsworth SJ, Powell GL, Barker SGE. Primary varicose veins: elevated plasma levels of the soluble isoform of the VEGF receptor flt-1. Phlebology 2003;18:48.
61. Cooper DG, Hillman-Cooper CS, Barker SGE, Hollingsworth SJ. Primary varicose veins: the sapheno-femoral junction, distribution of varicosities and patterns of incompetence. Eur J Vasc Endovasc Surg 2003;25:53-59. doi:10.1053/ejvs2002.1782.
62. C. Colorectal